{
  "source": "PA-Notification-Pulmozyme.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1084-13\nProgram Prior Authorization/Notification\nMedication Pulmozyme® (dornase alfa)\nP&T Approval Date 8/2012, 5/2013, 2/2014, 2/2015, 2/2016, 2/2017, 2/2018, 2/2019,\n2/2020, 2/2021, 2/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nPulmozyme (dornase alfa) is a recombinant deoxyribonuclease (DNase) enzyme indicated in\nconjunction with standard therapies for the management of cystic fibrosis (CF) patients to\nimprove pulmonary function.\nIn CF patients with a forced vital capacity (FVC) ≥ 40% of predicted, daily administration of\nPulmozyme has also been shown to reduce the risk of respiratory tract infections requiring\nparenteral antibiotics.1\nMembers will be requi red to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Pulmozyme will be approved based on both of the following criteria:\na. Diagnosis of cystic fibrosis\n-AND-\nb. Used in conjunction with standard CF therapies [e.g., chest physiotherapy,\nbronchodilators, antibiotics, anti-inflammatory therapy (e.g., ibuprofen, oral/inhaled\ncorticosteroids)]\nAuthorization of therapy will be issued for 12 months.\nB. Reauthorization\n1. Pulmozyme will be approved based on the following criterion:\na. Documentation of positive clinical response to Pulmozyme therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4.",
    "im/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Pulmozyme [package insert]. South San Francisco, CA: Genentech, Inc.; July 2021.\n2. Mogayzel P, Naureckas E, Robinson K, Mueller G, Hadjiliadis D, Hoag J, Lubsch L,\nHazle L, Sabadosa K, Marshall B; Cystic fibrosis pulmonary guidelines. Chronic\nmedications for maintenance of lung health. American Journal of Respiratory and Critical\nCare Medicine 2013;187:680-689.\nProgram Prior Authorization/Notification - Pulmozyme (dornase alfa)\nChange Control\n2/2014 Updated authorization to 60 months. Removed reauthorization criteria.\n2/2015 Annual review with no change to coverage criteria. Updated references.\n2/2016 Annual review with no changes to clinical content. Changed\nauthorization period to 12 months and added re-authorization period for\n12 months. Administrative changes only to background section.\nUpdated reference.\n2/2017 Annual review with no changes to coverage criteria.\n2/2018 Annual review with no changes to coverage criteria.\n2/2019 Annual review. Updated references. Updated background information.\n2/2020 Annual review. Updated background. No changes to coverage criteria.\n2/2021 Annual review. No changes to coverage criteria.\n2/2022 Annual review with no changes to coverage criteria. Updated\nreferences.\n2/2023 Annual review. No changes to coverage criteria. Added state mandate\nfootnote.\n2/2024 Annual review with no changes to coverage criteria.\n2/2025 Annual review with no changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}